Clinical Trial Detail

NCT ID NCT02003222
Title Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute lymphoblastic leukemia

Therapies

Cytarabine

Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate

Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate

Cyclophosphamide + Cytarabine + Mercaptopurine + Pegaspargase

Methotrexate + Pegaspargase

Cytarabine + Etoposide + Methotrexate

Rituximab

Blinatumomab

Age Groups: adult senior

No variant requirements are available.